Coelho et al.1 reported no significant changes in this trial even though transthyretin (TTR) was stabilized in all patients receiving Tafamidis. However, various methodologic aspects may have influenced the results.
No takes yet. Share an insight, caveat, or question.
Ingemar S.J. Merkies (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: